PANLAR consensus statement on biosimilars

Simple item page
dc.contributor.authorSérgio Cândido Kowalski
dc.contributor.authorJ. A. Benavides
dc.contributor.authorP. A. B. Roa
dc.contributor.authorClaudio Galarza-Maldonado
dc.contributor.authorCarlo V. Caballero‐Uribe
dc.contributor.authorEnrique R. Soriano
dc.contributor.authorCarlos Pineda
dc.contributor.authorValderílio Feijó Azevedo
dc.contributor.authorG. Ávila
dc.contributor.authorAlejandra Babini
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:17:20Z
dc.date.available2026-03-22T14:17:20Z
dc.date.issued2019
dc.descriptionCitaciones: 18
dc.identifier.doi10.1007/s10067-019-04496-3
dc.identifier.urihttps://doi.org/10.1007/s10067-019-04496-3
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/45639
dc.language.isoen
dc.publisherSpringer Science+Business Media
dc.relation.ispartofClinical Rheumatology
dc.sourceUniversidade Federal do Paraná
dc.subjectBiosimilar
dc.subjectMedicine
dc.subjectPharmacovigilance
dc.subjectTraceability
dc.subjectDelphi
dc.subjectDelphi method
dc.subjectFamily medicine
dc.subjectActuarial science
dc.subjectAdverse effect
dc.titlePANLAR consensus statement on biosimilars
dc.typearticle

Files

Collections

Artículo Científico Publicado